Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II
-
Abstract Number: 3173
Pan-PPAR Agonist IVA337 Is Effective in the Prevention of Experimental Lung Fibrosis and Related Pulmonary Hypertension
-
Abstract Number: 3174
Apremilast Attenuates the Fibrogenic Phenotype of Dermal Fibroblasts from Patients with Systemic Sclerosis, Contributing to the Prevention of the Progression of Experimental Dermal Fibrosis
-
Abstract Number: 3175
Longitudinal Analysis of MMF Clinical, Molecular, and Immunohistochemistry (IHC) Responses Shows SSc Patients Lose Their Inflammatory Signature and Rebound upon Treatment Cessation
-
Abstract Number: 3176
Meta-Analysis of SSc Clinical Trials with Molecular Gene Expression Data Suggests Potential Combination Therapies